← All trials
NCT00107081
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2004
- Primary completion
- Dec 1, 2007
- Completion date
- Dec 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Swiss Pediatric Oncology GroupLead sponsor
- Swiss Cancer LeagueCollaborator
- University of GroningenOverall official - principal investigator
- University of LausanneOverall official - principal investigator
- University of ZurichOverall official - principal investigator
- University of BernStudy chair
- University of BernStudy director
- University of ZurichStudy director
- BayerCollaborator
- GlaxoSmithKlineCollaborator
- University of BaselOverall official - principal investigator
- University of BonnOverall official - principal investigator
- University of GenevaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.